This study examines whether repeated magnetic resonance imaging (MRI)s scan helps identify changes in the tumor during radiation and chemotherapy treatment in patients with high grade glioma. Additional MRIs scan may help researchers to see changes in the status of the disease. Seeing these changes may result in changes to the treatment plan.
PRIMARY OBJECTIVES: I. To compare the radiation dosimetric coverage of the surgical cavity and any residual tumor when the immediate post-operative MRI is used versus (vs.) newly acquired MRI prior to radiation therapy. II. To evaluate the cumulative dosimetric differences for the target volume and normal structures between an adaptive radiotherapy approach based on serial MRI vs. the conventionally delivered radiotherapy plan using the target and normal structure volumes from the initial MRI simulation. SECONDARY OBJECTIVES: I. To report the incidence of tumor progression between surgery and radiation therapy and factors related to higher risk of tumor progression (e.g. Time interval between surgery and radiation, extent of surgery, molecular characteristics). II. To evaluate the relationship between the delivered dosimetry and patterns of failure and changes in neurocognitive function. III. To evaluate the relationship between voxel-wise quantitative changes on multiparametric MRI including apparent diffusion coefficient (ADC), fractional anisotropy (FA), relative cerebral blood volume (rCBV), fractional volume of the extravascular, extracellular space (ve) and Ktrans (transfer constant that characterizes the diffusive transport of low-molecular weight gadolinium across the capillary endothelium) with patterns of failure and changes in neurocognitive function. IV. To determine if early post-operative progression is associated with worse overall survival. V. To determine the difference in reported pseudoprogression at first follow-up after completing radiation when the baseline MRI is the immediate post-op MRI vs. newly acquired MRI prior to radiation therapy. VI. To compare image co-registration accuracy between the radiation planning computed tomography (CT) images and MRI for the immediate post-op MRI vs. newly acquired MRI prior to radiation therapy. VII. To evaluate the relationship between standard clinical neurocognitive function (NCF) and iPad based NCF (iNCF) test results. OUTLINE: Patients undergo MRI with and without contrast immediately before radiotherapy (for radiation planning) and at mid treatment (week 3). Patients also undergo MRI without contrast on weeks 1, 2, 4, 5, and 6 of radiotherapy. Patients may also undergo neurocognitive function testing over 70 minutes before treatment, at the end of each week of treatment, and at 3 and 6 months after completion of treatment.
Study Type
OBSERVATIONAL
Enrollment
80
M D Anderson Cancer Center
Houston, Texas, United States
RECRUITINGDifferences in the delineated target and organ at risk volumes and dosimetry
Will be compared between the plans generated using the immediate post-op MRI versus (vs.) MR simulation. A Kolmogorov-Smirnov test will be used to assess distributional (histogram) changes between the two scenarios.
Time frame: Up to 2 years
Cumulative dosimetric differences for the target volume and normal structures
Cumulative dosimetric differences for the target volume and normal structures between an adaptive radiotherapy approach based on serial MR images vs. the conventionally delivered radiotherapy plan. A Kolmogorov-Smirnov test will be used to assess distributional (histogram) changes between the two scenarios.
Time frame: Up to 2 years
Incidence and temporal relationship of tumor progression between surgery and radiation therapy
Specifically, the rate of change in volume between surgery and radiation therapy (RT) will be measured and reported.
Time frame: Up to 2 years
Local tumor control
Local control is defined as stable disease, partial response or complete response using Response Assessment in Neuro-Oncology (RANO) criteria.
Time frame: At 6 months post-treatment
Local tumor control
Local control is defined as stable disease, partial response or complete response using RANO criteria.
Time frame: At 12 months post-treatment
Overall survival (OS)
A Cox proportional hazards regression model will be constructed to associate post-op progression with OS, after adjusting for age, IDH mutation, Karnofsky performance status and extent-of-resection.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Ancillary studies
Time frame: From the date of start of radiation to the date of death, assessed up to 2 years
Changes in co-registration accuracy under the two settings
A paired t-test (or a nonparametric analog) will be used to assess changes in co-registration accuracy under the two settings (post-op MRI vs. newly acquired MRI prior to radiation therapy).
Time frame: Baseline up to 2 years
Difference in reported pseudoprogression
Will determine the difference in the reported incidence of pseudoprogression at first follow-up after completion of 6 weeks of radiation when the immediate post-resection MRI is used as the baseline vs. newly acquired MRI prior to radiation therapy as the baseline. A binomial test of proportions between reported pseudo-progression in postsurgical MRI vs. baseline pre-radiation MRI with contrast will be performed.
Time frame: Up to 6 weeks after completion of radiation
Dosimetric differences
Will be assessed via paired t-test (or a nonparametric analog).
Time frame: Up to 2 years